Topical estrogens for the treatment of superficial dyspareunia related to genitourinary syndrome of menopause in women with a history of endometriosis
A clinical dilemma
Bibliographic Data
| ID | 23198546 |
|---|---|
| Authors | Raymond Weil (corresponding author), G E Cetera, C E M Merli, V Boero, C Caia, P Vercellini |
| Year | 2023 |
| Volume | 288 |
| Issue | 2 |
| Pages | 12-17 |
| Publication date | 2023-09-01 |
| Peer Reviewed | Yes |
| Open Access | Yes |
| Type | ARTICLE |
| Venue | European Journal of Obstetrics & Gynecology and Reproductive Biology (JOURNAL) |
| Journal identifiers | ISSN: 0301-2115 • E-ISSN: 0301-2115 |
| Publisher | Elsevier BV (PUBLISHER) |
| DOI | 10.1016/j.ejogrb.2023.06.025 |
| OpenAlex | W37421742 |
| Language | EN |
| Citations received | 6 |
| References cited | 81 |
Estrogen withdrawal, which occurs with the cessation of ovulation, causes genitourinary syndrome of menopause in up to 50-85% of women. Symptoms may profoundly impact quality of life and sexual function, interfering with enjoyment of sex in up to three out of four individuals. Topical estrogens have been found to provide symptom relief with minimal systemic absorption and appear to be superior to systemic therapy as what regards genitourinary symptoms. However, conclusive data on their appropriateness in postmenopausal women with a history of endometriosis is not available and the hypothesis that exogenous estrogen stimulation may reactivate endometriotic foci or even promote their malignant transformation is still open. On the other hand, endometriosis affects around 10% of premenopausal women, many of which may be exposed to an acute hypoestrogenic depletion even before spontaneous menopause occurs. This considered, excluding on principle patients with a history of endometriosis from first-line treatment for vulvovaginal atrophy would mean excluding a considerable percentage of the population from adequate care. More robust evidence is urgently needed in these regards. Meanwhile, it would appear reasonable to tailor the prescription of topical hormones in these patients, taking into account the entity of symptoms and the impact such symptoms have on patients' quality of life, as well as the form of endometriosis and the possible risks hormonal may entail. Moreover, the application of estrogens on the vulva instead of the vagina could be efficacious, while outweighing the possible biological cost of hormonal treatment in women with a history of endometriosis.
Humanities · Classical Philosophy and Thought · Historical and Literary Analyses · Historical and Literary Studies · Philosophy
| Unique citing works | 6 |
|---|---|
| Citations per year | 0.19 |
| Citation span | 1994 - 2020 (27) |
| Citation velocity | historical |
| Highly cited | No |
| Citation types | Neutral: 3 |